221 related articles for article (PubMed ID: 31882409)
1. Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
Standl E; Stevens SR; Lokhnygina Y; Bethel MA; Buse JB; Gustavson SM; Maggioni AP; Mentz RJ; Hernandez AF; Holman RR;
Diabetes Care; 2020 Mar; 43(3):643-652. PubMed ID: 31882409
[TBL] [Abstract][Full Text] [Related]
2. Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.
Standl E; Stevens SR; Armstrong PW; Buse JB; Chan JCN; Green JB; Lachin JM; Scheen A; Travert F; Van de Werf F; Peterson ED; Holman RR;
Diabetes Care; 2018 Mar; 41(3):596-603. PubMed ID: 29311155
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
Sacre JW; Magliano DJ; Shaw JE
Diabetes Care; 2020 Oct; 43(10):2614-2623. PubMed ID: 32958618
[TBL] [Abstract][Full Text] [Related]
4. Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
Marx N; Kolkailah AA; Rosenstock J; Johansen OE; Cooper ME; Alexander JH; Toto RD; Wanner C; Espeland MA; Mattheus M; Schnaidt S; Perkovic V; Gollop ND; McGuire DK
JAMA Cardiol; 2024 Feb; 9(2):134-143. PubMed ID: 38170502
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.
Badjatiya A; Merrill P; Buse JB; Goodman SG; Katona B; Iqbal N; Pagidipati NJ; Sattar N; Holman RR; Hernandez AF; Mentz RJ; Patel MR; Jones WS
Circ Cardiovasc Interv; 2019 Dec; 12(12):e008018. PubMed ID: 31752517
[TBL] [Abstract][Full Text] [Related]
6. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
White WB; Kupfer S; Zannad F; Mehta CR; Wilson CA; Lei L; Bakris GL; Nissen SE; Cushman WC; Heller SR; Bergenstal RM; Fleck PR; Cannon CP;
Diabetes Care; 2016 Jul; 39(7):1267-73. PubMed ID: 27289121
[TBL] [Abstract][Full Text] [Related]
8. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
Bethel MA; Mentz RJ; Merrill P; Buse JB; Chan JC; Goodman SG; Iqbal N; Jakuboniene N; Katona B; Lokhnygina Y; Lopes RD; Maggioni AP; Ohman P; Tankova T; Bakris GL; Hernandez AF; Holman RR
Diabetes Care; 2020 Feb; 43(2):446-452. PubMed ID: 31757838
[TBL] [Abstract][Full Text] [Related]
9. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin.
Freemantle N; Danchin N; Calvi-Gries F; Vincent M; Home PD
Diabetes Obes Metab; 2016 Feb; 18(2):152-8. PubMed ID: 26511332
[TBL] [Abstract][Full Text] [Related]
10. Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus.
Barbery CE; Giczewska A; White J; Lokhnygina Y; Mentz RJ; Holman RR; Pagidipati N; Hernandez AF; Jones WS
Am Heart J; 2021 Sep; 239():59-63. PubMed ID: 33905751
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
12. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Holman RR; Bethel MA; Mentz RJ; Thompson VP; Lokhnygina Y; Buse JB; Chan JC; Choi J; Gustavson SM; Iqbal N; Maggioni AP; Marso SP; Öhman P; Pagidipati NJ; Poulter N; Ramachandran A; Zinman B; Hernandez AF;
N Engl J Med; 2017 Sep; 377(13):1228-1239. PubMed ID: 28910237
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience.
Zinman B; Marso SP; Christiansen E; Calanna S; Rasmussen S; Buse JB;
Diabetes Care; 2018 Aug; 41(8):1783-1791. PubMed ID: 29903847
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.
Holman RR; Bethel MA; George J; Sourij H; Doran Z; Keenan J; Khurmi NS; Mentz RJ; Oulhaj A; Buse JB; Chan JC; Iqbal N; Kundu S; Maggioni AP; Marso SP; Öhman P; Pencina MJ; Poulter N; Porter LE; Ramachandran A; Zinman B; Hernandez AF
Am Heart J; 2016 Apr; 174():103-10. PubMed ID: 26995376
[TBL] [Abstract][Full Text] [Related]
15. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
Shavadia JS; Zheng Y; Green JB; Armstrong PW; Westerhout CM; McGuire DK; Cornel JH; Holman RR; Peterson ED
Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
[TBL] [Abstract][Full Text] [Related]
16. Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.
El Khoury P; Roussel R; Fumeron F; Abou-Khalil Y; Velho G; Mohammedi K; Jacob MP; Steg PG; Potier L; Ghaleb Y; Elbitar S; Ragot S; Andreata F; Caligiuri G; Hadjadj S; Boileau C; Marre M; Abifadel M; Varret M; Hansel B
Diabetes Obes Metab; 2018 Apr; 20(4):943-953. PubMed ID: 29205760
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes.
Bethel MA; Stevens SR; Buse JB; Choi J; Gustavson SM; Iqbal N; Lokhnygina Y; Mentz RJ; Patel RA; Öhman P; Schernthaner G; Lecube A; Hernandez AF; Holman RR
Circulation; 2020 Apr; 141(17):1360-1370. PubMed ID: 32098501
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.
Buse JB; Bain SC; Mann JFE; Nauck MA; Nissen SE; Pocock S; Poulter NR; Pratley RE; Linder M; Monk Fries T; Ørsted DD; Zinman B;
Diabetes Care; 2020 Jul; 43(7):1546-1552. PubMed ID: 32366578
[TBL] [Abstract][Full Text] [Related]
19. Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
Elharram M; Sharma A; White W; Bakris G; Rossignol P; Mehta C; Ferreira JP; Zannad F
Am Heart J; 2020 Nov; 229():40-51. PubMed ID: 32916607
[TBL] [Abstract][Full Text] [Related]
20. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
Pratley RE; Husain M; Lingvay I; Pieber TR; Mark T; Saevereid HA; Møller DV; Zinman B;
Cardiovasc Diabetol; 2019 Nov; 18(1):156. PubMed ID: 31729990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
